Thyreogen
- Category
- Bioregulators
- Administration routes
- Oral
- Regulatory status
- Not FDA-approved
A thyroid-tissue-derived bioregulator peptide, marketed to support and normalize thyroid function in aging adults. The case remains weak: a small institute report includes a comparison group, but robust independent trials are lacking. The bigger concern is safety: interaction with thyroid medications, risk in hyperthyroid conditions, and a smaller allergy risk from bovine-derived material. Not an approved drug in the US, and supply is mainly unregulated products sold online.
This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer
Compiled from published research indexed through March 2026.
Overview
Thyreogen is a natural peptide bioregulator derived from the thyroid gland of young calves. Developed by Professor Vladimir Khavinson, it belongs to the Cytomaxes class and targets the thyroid gland, where it is designed to exert tissue-specific effects on thyroid cells, restoring disturbed thyroid tissue function and normalizing hormone production. It is closely related to Thyramin, another thyroid-targeting peptide bioregulator with a PubMed-indexed clinical study.
Thyroid gland pathology is one of the most widespread endocrine disorders, with age being a major risk factor for developing hypothyroid states. A PubMed-indexed study (PMID 16075681) describes the efficacy of peptide bioregulators in correcting reduced thyroid function, noting that Thyramin (the related bioregulator) exerts tissue-specific effects on thyroid gland cells and enables restoration of disturbed thyroid function, particularly in elderly patients where subclinical and manifest hypothyroidism affect quality of life.
Thyreogen is manufactured in capsule form and is marketed for supporting thyroid function during aging, environmental stress (particularly in iodine-deficient regions), and as part of comprehensive bioregulator anti-aging protocols. It addresses the endocrine component alongside Endoluten (pineal), Glandokort (adrenal), and other gland-specific bioregulators.
How it works in the body
A bioregulator peptide complex derived from thyroid tissue. It regulates gene expression in thyroid follicular cells involved in thyroid hormone (T3/T4) synthesis and secretion, helping normalize thyroid function without directly replacing hormones.
Research overview
Thyreogen shares its research base with Thyramin, a related thyroid peptide bioregulator. PMID 16075681 describes peptide bioregulator efficacy in correcting reduced thyroid function, highlighting the tissue-specific effects on thyroid cells and restoration of disturbed function. The broader Khavinson research program provides context on how organ-specific peptides regulate gene expression in targeted tissues. Thyreogen specifically is classified as a Cytomaxes (natural extract) while Thyramin is a related product line. Clinical evidence is limited to Russian studies on thyroid peptide bioregulators in elderly patients with hypothyroid states.
Who researches Thyreogen?
Commonly researched by
People researching longevity and anti-aging interventions
Studied for effects on aging pathways, cellular health, or lifespan extension.
People researching support for thyroid function in age-related hypothyroidism
One of the primary studied benefits of Thyreogen.
Important considerations for
Those who are pregnant or breastfeeding
AbsoluteNo human reproductive safety data exists for this peptide. Effects on fetal development are unknown.
Anyone under 18
AbsoluteNo pediatric safety data. Not recommended for use in minors.
Those with Known hypersensitivity
AbsoluteDiscontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).
Safety & interactions
General cautions
Pregnancy or breastfeeding
AbsoluteNo human reproductive safety data exists for this peptide. Effects on fetal development are unknown.
Children under 18
AbsoluteNo pediatric safety data. Not recommended for use in minors.
Known hypersensitivity
AbsoluteDiscontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).
How to read the ratings
- Benefits
- = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
- Risks
- = level of concern: High · Moderate · Low · Theoretical
- Interactions
- = direction with this peptide: Protective / Synergistic · Caution · Neutral
Risk summary(3)
Rated by level of concern
Interaction with thyroid medications
ModeratePMID 30567254; PMID 26895744
Risk in hyperthyroid conditions
ModeratePMID 26895744
Allergic reaction to bovine thyroid-derived peptides
LowNo published case reports; category-level reasoning
Interaction summary(8)
Rated by direction with this peptide
Levothyroxine (T4)
CautionModerateBovine thyroid-derived supplements have been found to contain unlabeled active thyroid hormone, so co-use risks additive over-replacement and iatrogenic thyrotoxicosis; check TSH/free T4 before and 6-8 weeks after starting.
PMID 26895744; PMID 30567254
Liothyronine (T3) and desiccated thyroid extract (NDT)
CautionModerateSame additive-hormone concern as levothyroxine but amplified, since T3-containing regimens already produce supraphysiologic post-dose peaks and leave less margin before symptomatic thyrotoxicosis.
PMID 30567254
Antithyroid drugs (methimazole, carbimazole, propylthiouracil)
CautionTheoreticalThe product's claimed action - restoring follicular-cell hormone synthesis - runs directly counter to the therapeutic goal of thionamide therapy, and any hormone contamination would blunt titration; no interaction study exists.
Mechanism-based (PMID 16075681 describes the intended thyroid-stimulating direction)
Radioactive iodine (I-131) therapy and iodinated contrast/amiodarone
CautionTheoreticalUndeclared iodine or thyroid hormone in an animal-tissue extract could alter thyroidal iodine uptake and confound I-131 dosimetry or post-treatment thyroid function assessment; discontinue well before scanning or ablation.
Mechanism-based; no published data on Thyreogen iodine content
Warfarin and other vitamin K antagonists
CautionTheoreticalAny shift in thyroid status changes clotting-factor turnover and warfarin sensitivity - a well-established effect of thyroid hormone therapy - so INR should be watched if thyroid parameters move on this product.
Class effect of thyroid-status change; not studied for Thyreogen
Insulin and oral antihyperglycemics
CautionTheoreticalImproving or destabilizing thyroid status alters insulin clearance and hepatic glucose output, so glycemic control may drift and require dose review; no direct data for this peptide.
Class effect of thyroid-status change; not studied for Thyreogen
Beta-blockers (propranolol, atenolol)
NeutralLowNo pharmacokinetic interaction is expected, but beta-blockade can mask the adrenergic symptoms (tachycardia, tremor) that would otherwise be the first warning of hormone over-exposure from a contaminated glandular product.
Mechanism-based; no published interaction data
Thyroid function testing (TSH, free T4, thyroglobulin assays)
CautionLowNot a drug interaction but a clinically important one: unregulated glandular content can suppress TSH and distort interpretation of thyroid panels and thyroglobulin surveillance, so disclose use to the ordering clinician.
PMID 26895744
Known risks(3)
Interaction with thyroid medications
ModerateThyroid-targeting peptides could theoretically affect thyroid hormone levels, potentially requiring adjustment of levothyroxine or other thyroid medications.
Risk in hyperthyroid conditions
ModerateShould not be used in uncontrolled hyperthyroidism without medical supervision.
Allergic reaction to bovine thyroid-derived peptides
LowTheoretical risk; no serious adverse events reported.
Drug interactions(2)
Levothyroxine and other thyroid hormones
Potential interaction; monitor TSH and thyroid levels closely
Antithyroid drugs (methimazole, PTU)
Theoretical antagonism; avoid concurrent use without medical supervision
Research & benefits
Evidence base
- Evidence Level
- Very Limited Evidence
- Total Studies
- 3
- Human Studies
- 50
Evidence includes a PubMed-indexed controlled clinical trial of the related Thyramin product (PMID 16075681) and Khavinson Institute reports. Direct clinical data for Thyreogen capsules specifically is minimal. The evidence base relies on extrapolation from the related Thyramin product and the general bioregulator research program.
Researched for(3)
Rated by confidence in the evidence
Support for thyroid function in age-related hypothyroidism
SpeculativeEvidence includes related-product research and a small institute report on oral Thyreogen; independent confirmation is lacking.
PMID 16075681
Thyroid cell metabolism normalization
SpeculativeMechanism-based only, no study of Thyreogen's effect on thyroid cell activity.
PMID 34834147; PMID 31808038
Endocrine system support in aging
SpeculativeExtrapolated from other peptide bioregulators, no controlled human data for Thyreogen.
PMID 11452647; PMID 25306656
Benefits(3)
Support for thyroid function in age-related hypothyroidism
PMID 16075681 (Thyramin/thyroid bioregulator review)
Thyroid cell metabolism normalization
Khavinson Institute research program; tissue-specific peptide data
Endocrine system support in aging
Khavinson bioregulator research; used in comprehensive endocrine protocols
Key studies(1)
Peptide bioregulator efficacy in the correction of reduced thyroid function
Controlled clinical trial of ThyraminVariableKhavinson VKh et al.
Advances in Gerontology
2005
Thyroid peptide bioregulators (Thyramin) show tissue-specific effects on thyroid cells and enable restoration of disturbed thyroid function, particularly important in elderly patients with subclinical and manifest hypothyroidism.
Regulation & availability
Why researchers look at it
Thyreogen targets thyroid cell function with organ-specific peptides, addressing one of the most common age-related endocrine disorders. It is part of Khavinson's comprehensive endocrine bioregulator system alongside Endoluten and Glandokort.
- Estimated cost
- $30-60/mo (capsules)
- FDA status
- Not FDA-approved; not reviewed by FDA; sold as dietary supplement internationally
- WADA status
- Not individually named. WADA S0 prohibits pharmacological substances not covered by later sections of the List that lack current approval from any governmental health authority for human therapeutic use. Supplement registration does not establish that approval; product-specific anti-doping confirmation is needed.
- Prescribability
- Available in Russia as dietary supplement; not approved in USA/EU
- Availability
- Manufactured by GARMONIA Ltd. Not available through conventional pharmacies in USA/EU.
International status
EU
Not approved
US
Not approved
Russia
Used clinically (Khavinson bioregulator protocol)
Worldwide
Limited to Russian clinical use
Regulatory timeline(2)
- 2000sDeveloped and commercialized as Cytomaxes supplement in Russia
- 2005PubMed-indexed controlled clinical trial of the related thyroid bioregulator Thyramin published
Sources & FAQs
Research sources(2)
Frequently asked questions(3)
Can Thyreogen replace thyroid medication?
No. Thyreogen is a dietary supplement, not a drug. It should not replace prescribed thyroid medications like levothyroxine. Patients on thyroid medication should consult their endocrinologist before adding any thyroid-targeting supplement.
Is Thyreogen safe for people with hyperthyroidism?
Thyreogen is described as normalizing (regulatory) rather than purely stimulatory. However, individuals with hyperthyroidism or Graves' disease should exercise extreme caution and consult an endocrinologist, as thyroid-targeting peptides could theoretically exacerbate overactive thyroid conditions.
How is Thyreogen related to Thyramin?
Both target the thyroid gland. Thyreogen is classified as a Cytomaxes (natural peptide complex from animal thyroid tissue), while Thyramin is a related product from the same research program. They share the same mechanistic basis.